Though MGMT promoter is methylated in up to 60% of GBM cases, for the first nine months of follow-up, addition of TMZ to radiotherapy does not change survival outcome[4], suggesting that MGMT methylation is the not the sole factor determining outcome. This evidence concerns the gene MGMT and glioblastoma.